Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aldo-keto reductase family 7 member A2 (AKR7A2)
- Target
- AKR7A2
- Molecular classification
- Enzyme, Aldo-keto reductase
01
Overview
Aldo-keto reductase family 7 member A2 (AKR7A2) is an enzyme in the aldo-keto reductase superfamily that catalyzes the NADPH-dependent reduction of succinic semialdehyde to gamma-hydroxybutyrate (GHB), playing a critical role in both detoxification of aldehydes and neuromodulator biosynthesis. It protects cells from oxidative injury by reducing reactive aldehydes such as those produced from lipid peroxidation, and is implicated in the metabolic breakdown and detoxification of the potent hepatocarcinogen aflatoxin B1. AKR7A2 is highly expressed in the liver and neural tissues, positioning it as a multifunctional detoxification and metabolic enzyme linked to defense against liver cancer and to neuromodulatory processes in the brain.
- Other names
- Aflatoxin B1 aldehyde reductase member 2AFARAFAR1AFB1-AR1AKR7Aldo-keto reductase family 7, member A2Aflatoxin aldehyde reductase
02
Mechanism of action
Detoxication: NADPH-dependent reduction of toxic aldehydes and aflatoxin B1 derivatives; Enzymatic reduction in neurotransmitter and xenobiotic metabolism
03
Biological functions
Detoxification of aldehydes and ketonesCellular defense against oxidative stressCatalysis of succinic semialdehyde reduction to gamma-hydroxybutyrate (GHB)Protection from toxic and carcinogenic effects of aflatoxin B1Energy production and conversion
04
Disease associations
Cancer (specifically, protection against hepatocarcinogenic effects of aflatoxin B1)Neurodegenerative disease (impacts neuromodulator GHB, and neurotransmitter metabolism)
05
Safety considerations
Altered AKR7A2 activity may affect detoxification capacity, potentially influencing susceptibility to aflatoxin toxicity (and risk of hepatocellular carcinoma).Modulation may impact neurotransmitter levels (gamma-hydroxybutyrate), raising concerns for neurological effects.
06
Interacting drugs
No specifically approved or clinically used drugs directly targeting AKR7A2 were identified. However, its expression or activity can be affected by compounds such as aflatoxin B1 and various aldehydes.
07
Biomarkers
No established biomarkers for patient selection or therapeutic monitoring were identified in public datasets or literature.
Beyond the preview
Go deeper on Aldo-keto reductase family 7 member A2 (AKR7A2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aldo-keto reductase family 7 member A2 (AKR7A2).